evoq bpc 157 BPC-157 Injectable Peptide for Healing & Recovery BPC-157 - Rocky Mountain Peptides

& Wu, L

Details SHOW SMILES / InChI SMILES CCCCCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCCCCCC(N)=O InChI InChIKey=XEUVNVNAVKZSPT-JTJYXVOQSA-N InChI=1S/C27H44N4O5/c1-4-6-8-12-24(34)30-22(18-20-13-15-21(32)16-14-20)26(35)31-25(19(3)5-2)27(36)29-17-10-7-9-11-23(28)33/h13-16,19,22,25,32H,4-12,17-18H2,1-3H3,(H2,28,33)(H,29,36)(H,30,34)(H,31,35)/t19-,22-,25-/m0/s1 Approval Year ACTIVE MOIETY PRODRUG (METABOLITE ACTIVE)

Half-life values are derived from specific assay conditions typically IV bolus administration in a single species with healthy plasma and may not reflect the pharmacokinetics observed under different experimental circumstances

Similarly, in large-cell anaplastic rhabdomyosarcoma, the HGF/c-Met pathway and c-Myc collaboratively promote the development of large cell dedifferentiated rhabdomyosarcoma